The W Fund plans to invest $250,000 to $500,000 in about 25 to 30 early-stage companies over the next five years, focusing efforts on upstarts that have strong ties to research universities in the state.
“The University of Washington today (2/8/2012) unveiled a new business incubator that will provide startup businesses access to critical lab and office space on the UW campus for their work.
The incubator is one key element in a larger commercialization initiative announced by President Michael Young today that will double the number of startups produced by the UW – from an average of 10 a year to 20 – during the next three years.
The UW Center for Commercialization New Ventures Facility, which opened today, showcases the UW’s commitment to spinning out an increasing number of companies built around UW research. The incubator will be led by the UW Center for Commercialization New Ventures program and is located in UW’s Fluke Hall.
The space will initially host 15 companies and when finished will have space for 25 startups, providing 11,500 square feet of lab space and 11,500 square feet of office space…”
J&J has been moving quickly the past few months on a new initiative to help biotech startups get up and running…
“Johnson & Johnson’s West Coast research leader, Diego Miralles, has met with a lot of biotech entrepreneurs who are curious about what J&J is doing to foster more startups at its facility in San Diego. At some point, a skeptical question usually comes up.
“What’s the catch?” Miralles says he’s sometimes asked.
He insists there isn’t any catch.
“We are genuinely trying to help the industry,” Miralles said last week in a meeting at the JP Morgan Healthcare Conference in San Francisco. “We think helping the biotech industry helps us. We strongly believe that a rising tide lifts all ships.”
J&J (NYSE: JNJ), which is based in New Brunswick, NJ, has been moving quickly the past few months on a new initiative to help biotech startups get up and running, through its new 30,000 square foot Janssen Labs startup space on the Torrey Pines Mesa. As Bruce first reported here in October, the idea is to create a space at J&J’s facility where 18-20 fledgling companies can get modern lab space, supplies, professional facilities management, and equipment that is supposed to free up the entrepreneurs to focus more on their science…”
NYC plays catch-up to create centers, attract venture capital.
From Crain’s NY Business:
“In recent years, the Bloomberg administration and its partners in academia and business have worked to overcome barriers to commercial biotech, from lack of space to lack of funding. The focus is now turning to what some consider the most difficult obstacle: a scarcity of entrepreneurial instinct in a medical-science community that widely thinks “going commercial” means to succumb to the dark side. From networking and pitching events to mentoring, advocates are trying to build the kind of startup ecosystem that has helped make the city’s Internet industry the fastest growing in the country.
“Innovation is a mindset; it’s a culture,” said Jonathan Lewis, a former Memorial Sloan-Kettering Cancer Center surgeon, and founder and CEO of Manhattan-based cancer-drug developer Ziopharm Oncology Inc. “It’s been applied to high-tech, and now it has to be applied to biotech.”
It remains to be seen whether such efforts can replicate here what developed organically in biotech hot spots like Boston and San Francisco. Venture capitalists expect that it will take years, along with a string of successful companies and a coterie of seasoned biotech entrepreneurs who can invest in and mentor the next generation of startups…”
The idea is to remove the wall between discovery at universities and implementation in the economy.
From Cincinnati News:
“Dean Carlo Montemagno believes that some of the best teachers at the University of Cincinnati are dreaming up products that could change the world.
They’re partnering with corporations like GE Aviation, Procter & Gamble and Ethicon Endo-Surgery to apply that research or start their own companies. And they’re providing students with real-world experience that readies them for careers.
Montemagno, dean of the College of Engineering and Applied Science, is an entrepreneurial pioneer for UC. This month, he raised $50 million in funding from the state of Ohio and GE Aviation to start a new research institute at the university…”
Incubators run by universities and economic development groups have long provided the facilities, expertise and even funding to help biotechs bridge the valley of death. But incubators run by drug companies have garnered mixed results.
From Seeking Alpha:
“Johnson & Johnson (JNJ) [has announced] the launch of Janssen Labs at San Diego, a 30,000-square-foot incubator designed to serve as the future home for 18 to 20 biotech start-ups.
Companies in the J&J incubator will get access to their own space, as well as common areas that house equipment for nuclear magnetic resonance, mass spectrometry, flow cytometry and other analyses. In exchange for short, renewable leases, they will get “cost-efficient, flexible, turnkey wet labs…”
READ FULL ARTICLE [web]
The incubator has one single goal. To help create great companies that will call NYC home.
From the Business Insider:
“It’s very rare that a joint effort between the public, private, and education sector comes together to produce meaningful results. However, The Varick Street Incubator may be a shining example and roadmap for other cities to follow on how to foster tech innovation.
After spending time at various incubators in the city, it very well may be that the Varick Street incubator is the top place in NYC for new entrepreneurs to call home. If you get the opportunity to be at Varick Steet, you enjoy a lot of benefits. The incubator does not ask for any equity in your company. The rent is really affordable and includes a lot of amenities that are not free at other incubators. Best of all, you get access to high quality interns / employees from NYU, potential seed investors, NYU faculty advisors, and assistance from dozens of other private partners involved with the incubator. Probably one of the best benefits is that several serial entrepreneurs call the incubator home and serve as mentors and motivation for first time founders…”
The analysis examined the performance of the university’s startups over the past 30 years — including the 104 spinoff companies launched by the U-M Technology Transfer Office over the last decade. U-M analyzed how the university’s endowment would have performed if it had invested in those startups at an early stage.
“The University of Michigan’s decision to invest up to $25 million in its own startup companies offers a telling glimpse at how the university is balancing its investment pursuits with a stated desire to boost the economy.
The move also revealed a private debate in which U-M executives clashed over whether the university’s own spinoff companies were worthy of cash.
U-M President Mary Sue Coleman announced Wednesday morning that U-M’s $7.8 billion endowment would deliver up to $500,000 to every early-stage U-M startup that has already secured venture capital from an outside source.
It’s an admission that the university has missed out on past investment opportunities that would have helped its own startup companies expand — and earned the university’s endowment big financial returns…”